AZN - AstraZeneca PLC ADR - Stock Price & Dividends

AstraZeneca PLC is a biopharmaceutical company that specializes in the discovery, development, manufacturing, and commercialization of prescription medicines. The company's product portfolio is diverse and extensive, with a focus on addressing various health conditions across different therapeutic areas.

In the realm of cardiovascular, renal, metabolism, and oncology, AstraZeneca's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp. These medicines are designed to improve patient outcomes and address significant unmet medical needs.

In addition to its core therapeutic areas, AstraZeneca also has a range of products for COVID-19 and rare diseases, including Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma. These products demonstrate the company's commitment to addressing emerging global health challenges and providing innovative solutions for patients with rare and debilitating conditions.

AstraZeneca's commercialization strategy involves serving primary care and specialty care physicians through a network of distributors and local representative offices across the globe, including the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. This enables the company to reach a broad patient population and make its medicines accessible to those who need them most.

The company is also engaged in various collaborations and partnerships to drive innovation and advance its pipeline. For instance, it has agreements with Neurimmune AG to develop and commercialize NI006, with BenevolentAI for drug discovery in systemic lupus erythematosus, and with Absci Corporation for AI-driven drug discovery against an oncology target. These partnerships demonstrate AstraZeneca's commitment to leveraging cutting-edge technologies and expertise to accelerate the development of new medicines.

Founded in 1992 and headquartered in Cambridge, the United Kingdom, AstraZeneca PLC has a rich history of innovation and a strong track record of delivering life-changing medicines to patients around the world. The company's website can be accessed at https://www.astrazeneca.com.